BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...receptor 1c isoform (FGFR1c) complex activator Ph I (n=30) Will present data comparing NGM313 to pioglitazone...
BioCentury | Mar 16, 2018
Emerging Company Profile

Cirius safety

...to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone...
...blocks thiazolidinedione-induced fluid retention.” Proceedings of the National Academy of Sciences (2005) Jaime de León, Staff Writer Actos Avandia MSDC-0602 MSDC-0602K pioglitazone rosiglitazone Cirius...
BioCentury | Mar 15, 2018
Emerging Company Profile

Stabilizing damaged goods

...is in preclinical testing for cataracts. Takeda Pharmaceutical Co. Ltd. markets the PPARγ agonist Actos pioglitazone...
...and GW Pharmaceuticals plc, have products in the clinic for the indication. Marketed TZDs like Actos...
BioCentury | Feb 2, 2018
Clinical News

Takeda, Zinfandel's AD test fails to deliver

...Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial of 0.8 mg pioglitazone (AD-4833...
...ADCS-ADL-PI). Pioglitazone is a thiazolidinedione (TZD) PPAR gamma agonist insulin sensitizer. Takeda markets pioglitazone as Actos...
...adults with Type II diabetes. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Actos pioglitazone (AD-4833...
BioCentury | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

...Pharmaceuticals Inc. and used in conjunction with a Phase III trial of the PPARγ agonist pioglitazone...
...announced they had discontinued that trial because of an inadequate treatment effect. Takeda also markets pioglitazone...
BioCentury | Jan 25, 2018
Clinical News

Takeda, Zinfandel’s AD test fails to deliver

...Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMORROW trial of 0.8 mg pioglitazone (AD-4833...
...has exclusive, worldwide rights to develop and commercialize Zinfandel’s TOMM40 assay, including in combination with pioglitazone...
...analyze the data, including the performance of the algorithm, and present at a future meeting. Pioglitazone...
BioCentury | Oct 5, 2017
Strategy

Fixing FDA’s FAERS

...about marketed drugs. A time-resolved analysis of two PPARγ agonists marketed for diabetes -- Actos pioglitazone...
...steady stream of CV AEs entered into the system since its approval, virtually all of Actos’...
BioCentury | Jun 1, 2017
Company News

Strekin raises CHF10 million

...a series A round in late 2017 or early 2018. STR001 is a formulation of pioglitazone...
BioCentury | Apr 14, 2017
Finance

More NASH cash

...told BioCentury they were attracted to Cirius because of the efficacy of first-generation TZDs like pioglitazone...
...“What got us really excited about this opportunity was the increasing data coming out on pioglitazone...
...been shown for any drug in NASH,” Estes said. An investigator-led Phase IV trial of pioglitazone...
BioCentury | Apr 11, 2017
Financial News

NASH newco Cirius raises $40M in series A

...is designed to have an improved safety profile compared with first generation sensitizers such as pioglitazone...
Items per page:
1 - 10 of 428